MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable

Brief description of study

The purpose of this research study is to: • Test the safety of the study drug, pembrolizumab (MK-3475) • Test how your cancer responds to one of the following: o Pembrolizumab plus radiation therapy (RT) with or without cisplatin after surgery o RT with or without cisplatin after surgery.


Clinical Study Identifier: s18-00142
ClinicalTrials.gov Identifier: NCT03765918
Principal Investigator: Zujun Li
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.